Back to Journals » Journal of Blood Medicine » Volume 1

Emerging antithrombotic agents for thromboprophylaxis, clinical potential and patient considerations

Authors Borris L

Published 5 July 2010 Volume 2010:1 Pages 123—130


Review by Single-blind

Peer reviewer comments 3

Lars C Borris

Department of Orthopedics, Aarhus University Hospital, Aarhus, Denmark

Abstract: Patients undergoing major orthopedic surgery, total hip arthroplasty (THA) and total knee arthroplasty (TKA) are at high risk of venous thromboembolism, manifesting as deep vein thrombosis or pulmonary embolism. The recommended pharmacologic treatment options for thromboprophylaxis after major orthopedic surgery include the vitamin K ­antagonists (VKAs eg, warfarin), low molecular weight heparins (LMWHs; eg, enoxaparin) and the synthetic pentasaccharide fondaparinux. Most clinics use some kind of thromboprophylaxis routinely. However, due to the frequent need for coagulation monitoring (VKAs) and subcutaneous ­injections (LMWHs and fondaparinux) barriers exist to prescribing prophylaxis after discharge from hospital. Targeting specific components of the coagulation cascade has yielded several new antithrombotic agents for use as thromboprophylaxis after THA or TKA. Two of these, dabigatran etexilate and rivaroxaban, have already reached the markets in the European Union member states and Canada. Both are administered by the oral route, once-daily fixed dose and without the need to monitor the anticoagulant effect. Whether these new drugs facilitate guideline adherence, particularly in the outpatient settings and thereby improve the overall clinical outcomes remains to be shown.

Keywords: dabigatran etexilate, rivaroxaban, thromboprophylaxis, total joint arthroplasty, venous thromboembolism

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]